Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,327.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Raymond James on UnitedHealth Group (UNH): 'This was the cleanest UNH quarter reported in quite some time'April 22, 2026 9:45 AM UnitedHealth Group (UNH) PT Raised to $400 at Evercore ISI, 'Investors No Longer Livin' on [Just] a Prayer'April 21, 2026 3:11 PM Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverageApril 21, 2026 11:03 AM CVS Health Opts Out Of Medicare Obesity Drug Coverage ModelApril 21, 2026 10:53 AM UBS Reiterates Buy Rating on Eli Lilly (LLY)April 21, 2026 9:41 AM Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)April 21, 2026 7:19 AM Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INCApril 20, 2026 3:26 PM RBC Capital on Eli Lilly (LLY): Kelonia acquisition payment 'may appear full,' but strategically justifiedApril 20, 2026 11:20 AM RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'April 20, 2026 10:51 AM